Mycoses are fungal infections primarily caused by groups of fungi such as molds, yeasts, and dermatophytes. Dermatophytes such as Microsporum and Trichophyton cause fungal infections on the feet and the head. Yeasts cause infections at the mouth, genitals, and the esophagus. Pityrosporum and Candida are two examples of yeasts. Molds are primarily responsible for infections in internal organs, resulting in systemic mycoses. Systemic mycoses spread the fungi via the bloodstream to other organs, which causes multiple organ failures.
Forthcoming Structure for Mycoses Market can be obtained at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3112
Mycoses are caused because of a weakened immune system. People being treated with corticosteroids or patients with HIV/AIDS are prime examples of immune-compromised individuals. Some of the symptoms of mycoses are itchy and eczematous rashes, fever, itching, lumps and thickened skin, and loss of appetite and weight loss. Anemia, red skin patches, and enlarged liver and spleen are also some of the common signs of mycoses. Some of the other causes of mycoses are poorly controlled diabetes or being overweight. Any contact with contaminated towels or clothes may also cause mycoses. General physical examination, skin biopsy, immunophenotyping, complete blood count, and flow cytometry are some of the treatments for mycoses.
The global mycoses market is segmented on the basis of geography and treatment. Based on treatment, the global mycoses market is classified into chemotherapy, drug medication, photodynamic therapy, targeted therapy, and radiation therapy. Photodynamic therapy primarily uses laser light and a medicine to destroy various fungal cancer cells. Radiation therapy uses radiation or high-energy x-rays to prevent the fungal cells from spreading. Targeted therapy identifies the affected cells without harming normal or unaffected cells. Chemotherapy stops the development of the affected cells with the help of numerous medicines, either by killing the fungal cells or by preventing the division of cells. Drug medications or antifungal medications including caspofungin, amphotericin B, itraconazole, and fluconazole are used for treating mycoses.
Based on geography, the global mycoses market is divided into Europe, Asia Pacific, North America, and Rest of the World. At present, the global mycoses market is dominated by North America, followed by Europe. As per the National Institutes of Health, mycoses affect roughly 200,000 people in the U.S. every year. In the years to come, Asia Pacific is predicted to be the most promising market for companies in the global mycoses market owing to the large population base in nations such as India, China, and Japan. The changing lifestyles of people and the increasing prevalence of diabetes are also predicted to propel the Asia Pacific mycoses market in the next few years. Going forward, the global mycoses market is predicted to benefit from favorable reimbursement policies and tax benefits in developing countries.
Some of the leading companies operating in the global mycoses market are Bayer AG, Helix BioMedix, Inc., Pfizer, Inc., Moberg Derma AB, Pacgen Biopharmaceuticals Corporation, Xel Pharmaceuticals, Inc., Dr. Reddy’s Laboratories Limited, Merck & Co., Inc., Nuvo Research, Inc., Novabiotics Ltd, Quinnova Pharmaceuticals, Inc.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453